<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4773">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210170</url>
  </required_header>
  <id_info>
    <org_study_id>20071188</org_study_id>
    <secondary_id>P05299</secondary_id>
    <nct_id>NCT01210170</nct_id>
  </id_info>
  <brief_title>Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma</brief_title>
  <official_title>Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation
      transporters expressed by non-neuronal cells, thereby interfering with the inactivation of
      the organic cations by intracellular enzymes. Beta2-adrenergic agonists are organic cations,
      and the concentration of inhaled beta2-adrenergic agonists at beta2-adrenergic receptor
      sites on smooth muscle is likely to be increased by inhaled glucocorticosteroids (ICS) by
      the ICS' effect on the glucocorticosteroid-sensitive organic cation transporters. The
      investigators have shown in human airway vascular smooth muscle cells that the
      glucocorticosteroid action on organic cation uptake occurs within minutes, does not involve
      gene transcription or protein synthesis, is not mediated through classical steroid
      receptors, and is cell membrane-linked.

      In the present proposal, the investigators wish to use different single doses of mometasone,
      a clinically effective ICS, administered with or at different times before albuterol
      inhalation in subjects with moderate persistent asthma who are obstructed at the time of
      study.

      With this approach the investigators will test the hypothesis that a single inhalation of
      mometasone causes an acute, transient, dose-dependent potentiation of beta2-adrenergic
      bronchodilation.

      If the hypothesis that a single dose of mometasone acutely potentiates beta2-adrenergic
      bronchodilation is correct, the results would have a significant impact on treatment
      strategies involving ICSs and beta2-adrenergic agonists in patients with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen non-smokers (males and females between the ages of 18 and 65 years) with
      physician-diagnosed moderate persistent asthma will be recruited for the study. The subjects
      will be allowed to use inhaled controller (including ICS) and rescue medication. At study
      entry, all asthmatic subjects must be clinically stable, and have a forced
      pre-bronchodilator one-second expired volume (FEV1) of &lt; 75% predicted.

      Approval for the protocol will be requested from the University of Miami Institutional
      Review Board. All subjects will provide written informed consent.

      Exclusion criteria:

        -  Cardiovascular disease and use of cardiovascular medications

        -  Pregnancy

        -  Use of oral controller medication for asthma (methylxanthines, systemic
           glucocorticosteroids, leukotriene modifiers)

        -  An acute respiratory infection within 4 weeks before enrollment.

      Each subject will make 8 visits to the research laboratory.

      Procedures:

      Visit 1 (screening visit): On this visit, after having signed the consent form, the subjects
      will perform spirometry before and 15 min after inhaling 180 µg albuterol from a HFA-MDI
      using a spacer.

      Visit 2-8:Subjects that qualify for the study will be asked to return for 7 more visits for
      the following treatment protocols:

        -  Inhalation of 400 µg mometasone 30 min before inhalation of 180 µg albuterol

        -  Inhalation of mometasone placebo 30 min before inhalation of 180 µg albuterol

        -  Simultaneous inhalation of 400 µg mometasone and 180 µg albuterol

        -  Simultaneous inhalation of mometasone placebo and 180 µg albuterol

      Systemic blood pressure, pulse, O2 saturation, spirometry and airway blood flow ( Qaw) will
      be measured before mometasone or placebo inhalation, and before and 15 min after albuterol
      inhalation except on the day when mometasone and albuterol are co-administered; on that day
      the measurements will be made before and 15 min after the mometasone/albuterol
      co-administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Albuterol-induced Change in FEV1</measure>
    <time_frame>15 minutes after albuterol inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuterol Induced Percent Change in Qaw</measure>
    <time_frame>change in Qaw 15 minutes after albuterol inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>mometasone 200 mcg- 30 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 400 mcg - 30 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 400 mcg simultaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 400 mcg - 60 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo- 30 min</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo simultaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo- 60 min</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone 200 mcg</intervention_name>
    <description>participants received one of the intervention combinations on Day 1 of Week 1-4, in random order</description>
    <arm_group_label>mometasone 200 mcg- 30 min</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>participants received one of the intervention combinations on Day 1 of Week 1-4, in random order</description>
    <arm_group_label>placebo- 30 min</arm_group_label>
    <arm_group_label>placebo simultaneous</arm_group_label>
    <arm_group_label>placebo- 60 min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone 400 mcg</intervention_name>
    <description>participants received one of the intervention combinations on Day 1 of Week 1-4, in random order</description>
    <arm_group_label>mometasone 400 mcg - 30 min</arm_group_label>
    <arm_group_label>mometasone 400 mcg simultaneous</arm_group_label>
    <arm_group_label>mometasone 400 mcg - 60 min</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Fifteen non-smokers (males and females between the ages of 18 and 65
        years) with physician-diagnosed moderate persistent asthma and FEV1 &lt; 75% of predicted.

        Exclusion Criteria:Cardiovascular disease and use of cardiovascular medications,
        pregnancy, use of oral controller medication for asthma (methylxanthines, systemic
        glucocorticosteroids, leukotriene modifiers), an acute respiratory infection within 4
        weeks before enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Research Laboratory- University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 17, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2010</firstreceived_date>
  <firstreceived_results_date>September 5, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>asthma,</keyword>
  <keyword>inhaled corticosteroids,</keyword>
  <keyword>airway blood flow,</keyword>
  <keyword>mometasone,</keyword>
  <keyword>albuterol</keyword>
  <keyword>spirometry</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>• Inhalation of 400 µg mometasone DPI 30 min before inhalation of 180 µg albuterol
Mometasone furoate: • Inhalation of 400 µg mometasone or placebo DPI 30 min before inhalation of 180 µg albuterol
• Inhalation of 400 µg mometasone or placebo DPI 60 min before inhalation of 180 µg albuterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>• participant with asthma were enrolled in the study</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Albuterol-induced Change in FEV1</title>
        <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
        <time_frame>15 minutes after albuterol inhalation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>All Participants Received 400 mcg Mometasone-30 Min</title>
            <description>mometasone 400 mcg 30 minutes before albuterol 180 mcg inhalation</description>
          </group>
          <group group_id="O2">
            <title>All Participants Received Placebo 30 Minutes Before Albuterol</title>
            <description>mometasone placebo 30 minutes before albuterol 180 mcg inhalation</description>
          </group>
          <group group_id="O3">
            <title>All Participants Received 400 mcg Mometasone Simultaneous</title>
            <description>inhalation of 400 mcg mometasone immediately before inhalation of 180 mcg albuterol</description>
          </group>
          <group group_id="O4">
            <title>All Participants Received Placebo Simultaneously With Albutero</title>
            <description>inhalation of mometasone placebo immediately before inhalation of 180 mcg albuterol.</description>
          </group>
          <group group_id="O5">
            <title>All Participants Received 200 mcg Mometasone-30 Min</title>
            <description>mometasone 200 mcg 30 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
          <group group_id="O6">
            <title>All Participants Received 400 mcg -60 Min</title>
            <description>mometasone 400 mcg 60 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
          <group group_id="O7">
            <title>All Participants Received Placebo -60 Min</title>
            <description>placebo 60 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="15"/>
                  <measurement group_id="O6" value="15"/>
                  <measurement group_id="O7" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Albuterol-induced Change in FEV1</title>
            <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
            <units>liters</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.27" spread="0.04"/>
                  <measurement group_id="O2" value="0.18" spread="0.04"/>
                  <measurement group_id="O3" value="0.32" spread="0.04"/>
                  <measurement group_id="O4" value="0.20" spread="0.05"/>
                  <measurement group_id="O5" value="0.23" spread="0.04"/>
                  <measurement group_id="O6" value="0" spread="0"/>
                  <measurement group_id="O7" value="0" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albuterol Induced Percent Change in Qaw</title>
        <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
        <time_frame>change in Qaw 15 minutes after albuterol inhalation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone 30 Minutes Before Albuterol</title>
            <description>• Inhalation of 400 µg mometasone 30 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Placebo 30 Minutes Before Albuterol</title>
            <description>Inhalation of mometasone placebo 30 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O3">
            <title>Mometasone and Albuterol Simultaneously</title>
            <description>inhalation of 400 mcg mometasone immediately before inhalation of 180 mcg albuterol.</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Placebo and Albuterol Simultaneously</title>
            <description>inhalation of mometasone placebo immediately before inhalation of 180 mcg albuterol.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Albuterol Induced Percent Change in Qaw</title>
            <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
            <units>percent change in Qaw</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18" spread="3"/>
                  <measurement group_id="O2" value="0" spread="3"/>
                  <measurement group_id="O3" value="30" spread="7"/>
                  <measurement group_id="O4" value="-2" spread="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Simultaneous inhalation of 400 µg mometasone DPI and 180 µg albuterol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Wanner, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305) 243-2568</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
